← Human Trials & Peer-Reviewed Studies

Acute and chronic effects of exercise on inflammatory markers and B-type natriuretic peptide in patients with coronary artery disease

Plain-language guide to PMID 20835904 (2011): randomized controlled trial study of BNP (Nesiritide) in 34 patients.

Key Facts

PMID
20835904
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
Year
2011
Study type
Randomized Controlled Trial
Authors
Lara Fernandes J et al. (10 authors)
DOI
10.1007/s00392-010-0215-x

What This Study Did, in Plain Language

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

The researchers sought to evaluate the consequences of an acute bout of exercise on inflammatory markers and BNP in untrained CAD patients before and after randomization to a training program.

Why It Was Studied

Few studies have prospectively addressed the effects of exercise in the inflammatory activity of patients with coronary artery disease (CAD).

Who Took Part

According to the abstract, 34 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

They were then randomized to a 4-month chronic exercise program (15 patients) or general lifestyle recommendations (19 patients), undergoing a new acute session of exercise after that.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Acute Disease, Biomarkers, Chronic Disease, Coronary Artery Disease, Cytokines, Exercise and Exercise Test.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 34 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Clinical research in cardiology : official journal of the German Cardiac Society), a journal based in Germany.

More context: the BNP (Nesiritide) compound page, all human trials.

Our Notes on the Compound

BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.